Prostate Cancer Patients Disease Free After 5 Years Likely to Be Disease Free After 10 Years
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Prostate Cancer Patients Disease Free After 5 Years Likely to Be Disease Free After 10 Years

FAIRFAX, Va -- July 2, 2009 -- Patients with prostate cancer who receive brachytherapy and remain free of disease for 5 years or greater are unlikely to have a recurrence at 10 years, according to a study published in the July 1 issue of the International Journal of Radiation Oncology*Biology*Physics.

Lead author Richard Stock, MD, Department of Radiation Oncology, Mount Sinai Medical Center, New York, New York, and colleagues followed 742 patients with prostate cancer who were treated with brachytherapy alone, brachytherapy and hormonal therapy, or combined brachytherapy and external beam radiotherapy (EBRT) between 1991 and 2002.

None of the patients had recurred during their first 5 years post-treatment. They found that the prostate specific antigen (PSA) level taken at 5 years was an indicator of how well a patient would do in the future and the overall chance of being cancer free at 10 years was 97%.

In addition, none of the study participants developed metastatic disease or died from prostate cancer.

“Our data have indicated that improvements in treatment are continuing and that these will continue to have an effect on prostate brachytherapy data for years to come,” said Dr. Stock.

“Late failure rates will continue to decrease, making prostate brachytherapy alone and combined with hormonal therapy and/or EBRT an increasingly attractive treatment option.”

SOURCE: American Society for Radiation Oncology

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities